Karbimatsoli

Karbimatsoli, known in some languages as karbimatsoli, is an antithyroid medication in the thionamide class. It is a prodrug that is converted to methimazole in the body and works by inhibiting thyroid peroxidase, the enzyme responsible for the iodination and coupling steps in thyroid hormone synthesis. By reducing the production of thyroxine (T4) and triiodothyronine (T3), karbimatsoli helps control hyperthyroidism.

Uses and administration: It is used to treat hyperthyroidism due to Graves’ disease, toxic multinodular goitre, or toxic adenoma. It may also be employed to achieve a euthyroid state before thyroid surgery or radioactive iodine therapy and to control thyrotoxic symptoms while definitive treatment is planned. The medication is taken by mouth, usually as tablets, with dosing tailored to the individual and adjusted based on thyroid function tests. The clinical response develops over days to weeks, and thyroid tests are monitored to guide therapy.

Safety and monitoring: Common side effects include rash or itching. More serious but less frequent adverse effects include agranulocytosis, hepatotoxicity, and hypersensitivity reactions. Patients typically undergo baseline and periodic monitoring of blood counts and liver function, and should seek prompt medical attention for fever, sore throat, or unusual bruising.

Pregnancy and lactation: Karbimatsoli crosses the placenta. In many guidelines it is avoided in the first trimester due to potential congenital anomalies, with clinicians weighing risks and benefits and sometimes preferring alternative therapies. It is excreted in breast milk, so use during lactation requires careful consideration of risks and benefits.